Tananchai Petnak1,2, Charat Thongprayoon3, Wisit Kaewput4, Fawad Qureshi3, Boonphiphop Boonpheng5, Saraschandra Vallabhajosyula6, Tarun Bathini7, Michael A Mao8, Ploypin Lertjitbanjong9, Wisit Cheungpasitporn3. 1. Division of Pulmonary and Pulmonary Critical Care Medicine, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand. 2. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA. 3. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA. 4. Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok 10400, Thailand. 5. Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. 6. Section of Interventional Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA. 7. Department of Internal Medicine, University of Arizona, Tucson, AZ 85724, USA. 8. Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL 32224, USA. 9. Division of Pulmonary, Critical Care and Sleep Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Abstract
BACKGROUND: This study aimed to evaluate the risk factors for circulatory shock and its impact on outcomes in patients hospitalized for salicylate intoxication. METHODS: We used the National Inpatient Sample to identify patients hospitalized primarily for salicylate intoxication from 2003-2014. Circulatory shock was identified based on hospital diagnosis code for any type of shock or hypotension. We compared clinical characteristics, in-hospital treatments, outcomes, and resource use between patients with and without circulatory shock associated with salicylate intoxication. RESULTS: Of 13,805 hospital admissions for salicylate intoxication, circulatory shock developed in 484 (4%) admissions. Risk factors for development of circulatory shock included older age, female sex, concurrent psychotropic medication overdose, anemia, congestive heart failure, volume depletion, rhabdomyolysis, seizure, gastrointestinal bleeding, and sepsis. Circulatory shock was significantly associated with increased odds of any organ failure and in-hospital mortality. Length of hospital stay and hospitalization cost was significantly higher in patients with circulatory shock. CONCLUSION: Approximately 4% of patients admitted for salicylate intoxication developed circulatory shock. Circulatory shock was associated with worse clinical outcomes and increased resource use.
BACKGROUND: This study aimed to evaluate the risk factors for circulatory shock and its impact on outcomes in patients hospitalized for salicylate intoxication. METHODS: We used the National Inpatient Sample to identify patients hospitalized primarily for salicylate intoxication from 2003-2014. Circulatory shock was identified based on hospital diagnosis code for any type of shock or hypotension. We compared clinical characteristics, in-hospital treatments, outcomes, and resource use between patients with and without circulatory shock associated with salicylate intoxication. RESULTS: Of 13,805 hospital admissions for salicylate intoxication, circulatory shock developed in 484 (4%) admissions. Risk factors for development of circulatory shock included older age, female sex, concurrent psychotropic medication overdose, anemia, congestive heart failure, volume depletion, rhabdomyolysis, seizure, gastrointestinal bleeding, and sepsis. Circulatory shock was significantly associated with increased odds of any organ failure and in-hospital mortality. Length of hospital stay and hospitalization cost was significantly higher in patients with circulatory shock. CONCLUSION: Approximately 4% of patients admitted for salicylate intoxication developed circulatory shock. Circulatory shock was associated with worse clinical outcomes and increased resource use.
Authors: Peter A Chyka; Andrew R Erdman; Gwenn Christianson; Paul M Wax; Lisa L Booze; Anthony S Manoguerra; E Martin Caravati; Lewis S Nelson; Kent R Olson; Daniel J Cobaugh; Elizabeth J Scharman; Alan D Woolf; William G Troutman Journal: Clin Toxicol (Phila) Date: 2007 Impact factor: 4.467
Authors: David D Gummin; James B Mowry; Daniel A Spyker; Daniel E Brooks; Michael C Beuhler; Laura J Rivers; Heba A Hashem; Mark L Ryan Journal: Clin Toxicol (Phila) Date: 2019-11-21 Impact factor: 4.467